Triplezumab Combined With CAPEOX Regimen in Neoadjuvant Therapy for Locally Advanced Colon Cancer
Status:
Recruiting
Trial end date:
2021-03-04
Target enrollment:
Participant gender:
Summary
According to the 2019NCCN guidelines, immunocheckpoint inhibitors are recommended for
first-line treatment of metastatic colon cancer patients with high microsatellite instability
(msi-h) or mismatched gene deletion (dMMR) who are not suitable for intensive treatment, and
for all patients with second-line or above msi-h /dMMR treatment.This study is a
single-center, single-arm phase II study of the use of triplezumab (JS001) combined with
CAPEOX regimen in the neoadjuvant therapy of msi-h /dMMR for locally advanced colon cancer.
The subjects received neoadjuvant therapy with triplezumab (JS001) combined with CAPEOX
regimen, with one treatment cycle every 3 weeks and two cycles of surgery followed by
pathological evaluation.
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital of Xiamen University